Ares Genetics plans to launch the rapid tests developed by BGI and approved in China on the European market in February 2020.
The Chinese BGI Group, which has worked together with Ares Genetics for more than two years within the context of a strategic partnership, sequenced the genome of the new 2019-nCoV virus immediately after the first cases of the virus were identified in Wuhan, and successfully developed a Real-Time (RT) Fluorescent PCR (polymerase chain reaction) testing kit for detecting 2019-nCoV. This test provides results in a few hours and has already obtained approval by the Chinese National Medical Products Administration.
"Rapid molecular testing for 2019-nCoV and the monitoring of the further development of the virus based on genome sequencing are decisive in containing the spread of the coronavirus. Ares Genetics specialises in the genetic identification of bacterial pathogens and the prediction of antibiotic susceptibility. Within the context of our strategic partnership with GBI, we will bring testing procedures for 2019-nCoV to Europe", comments Dr. Andreas Posch, Managing Director and CEO of Ares Genetics.
Read more here about the Life Sciences Sector in Austria.